[1]
Royal College of Obstetrics and Gynaecologists: Management of
Suspected Ovarian Masses in Premenopausal Women; 162; Novembers. 2011.
[2]
Timmerman D, Van Calster B, Testa AC, et al. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol 2010; 36: 226-34.
[3]
Van Nagell JR, Miller RW. Evaluation and management of ultrasonographically detected ovarian tumors in asymptomatic women. Obstet Gynecol 2016; 127(5): 848-58.
[4]
Hermans AJ, Kluivers KB, Janssen LM, et al. Adnexal masses in children, adolescents and women of reproductive age in the Netherlands: A nationwide population-based cohort study. Gynecol Oncol 2016; 143(1): 93-7.
[5]
Moore RG, McMeekin DS, Brown AK, et al. A Novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with pelvic mass. Gynecol Oncol 2009; 112(1): 40-6.
[6]
Piovano E. Cavallero C1, Fuso L, et al Diagnostic accuracy and cost-effectiveness of different strategies to triage adnexal masses: A prospective study. Ultrasound Obstet Gynecol 2017; 50(3): 395-403.
[7]
Davidson SA. Management of the adnexal mass Danforth’s
Obstetrics and Gynecology, 10th Edition. 2008. 62: 1061-72.
[8]
Bennett JA, Oliva E. Pathology of the adnexal mass. Clin Obstet Gynecol 2015; 58(1): 3-27.
[9]
Brown J, Frumovitz M. Mucinous tumors of the ovary: Current thoughts on diagnosis and management. Curr Oncol Rep 2014; 16(6): 389.
[10]
Ahmed R, Din HU, Hashmi SN, Muhammad I. Sarcoma-like mural nodule in a borderline mucinous tumour of ovary. J Coll Physicians Surg Pak 2016; 26(5): 435-7.
[11]
Liggins CA, Ma LT, Schlumbrecht MP. Sertoli-Leydig cell tumor of the ovary: A diagnostic dilemma. Gynecol Oncol Rep 2016; 15: 16-9.
[12]
Pirschner F, Bastos PM, Contarato GL, Bimbato ACBL, Filho AC. Gorlin syndrome and bilateral ovarian fibroma. Int J Surg Case Rep 2012; 3(9): 477-80.
[13]
Lee KR, Scully RE. Mucinous tumors of the ovary: A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘pseudomyxoma peritonei’. Am J Surg Pathol 2000; 24: 1447.
[14]
Borah T, Mahanta RK, Bora BD, Saikia S. Brenner tumor of ovary: An incidental finding. J Midlife Health 2011; 2(1): 40-1.
[15]
Palmeiro MM, Cunha TM, Loureiro AL, Esteves G. A rare benign
ovarian tumour. BMJ Case Rep 2016; 2016 pii: bcr2015214101.
[16]
Burnik Papler T, Frković Grazio S, Kobal B. Sertoli-Leydig cell tumor with retiform areas and overgrowth of rhabdomyosarcomatous elements: Case report and literature review. J Ovarian Res 2016; 9: 46.
[17]
Baek J. Synchronous occurrence of mature cystic teratoma of the fallopian tube and ovary: A case report. Oncol Lett 2016; 12: 911-4.
[18]
Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas: Tumor types and imaging characteristics. Radiographics 2001; 21: 475-90.
[19]
Gupta A, Gupta P, Manaktala U, Khurana N. Clinical, radiological, and histopathological analysis of paraovarian cysts. J Midlife Health 2016; 7(2): 78-82.
[20]
American College of Obstetrics and Gynecology: Committee Opinion:
The Role of the Obstetrician Gynecologist in the Early Detection
of Epithelial Ovarian Cancer; no. 477, March. 2011.
[21]
Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2013. Bethesda, (MD): National Cancer Institute 2016.
[22]
American College of Obstetrics and Gynecology: Practice Bulletin
Evaluation and Management of Adnexal Masses; 174, November. 2016.
[23]
Li A. New Biomarkers for ovarian cancer: OVA1 and ROMA in
diagnosis, selective use of these new tests may lead to better outcomes
for women with adnexal masses or epithelial ovarian cancer.
Contemporary Obstetrics and Gynecology & Women’s health.
April 1, 2012.
[24]
US Food and Drug Administration. FDA clears a test for ovarian cancer: test can help identify potential malignancies, guide surgical decisions. Silver Springs, MD: FDA 2009.
[25]
Smorgick N, Maymon R. Assesment of adnexal masses using ultrasound: A practical review. Int J Womens Health 2014; 6: 857-63.
[26]
Pavlik EJ, Ueland FR, Miller RW, et al. Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstet Gynecol 2013; 122: 210-7.
[27]
Timmerman D, Testa AC, Bourne T, et al. Logstistic Regression model to distinguish between the benign and malignant adnexal mass before surgery: A multicenter study by the international ovarian tumor analysis group. J Clin Oncol 2005; 23: 8794-801.
[28]
Lynda Roman, Laila Muderspach, et al. Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet Gynecol 1997; 89(4): 493-500.
[29]
van Nagell JR, DePriest PD. Management of adnexal masses in postmenopausal women. Am J Obstet Gynecol 2005; 193(1): 30-5.
12
2